Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 1999;37:9-16; doi:10.1136/dtb.1999.3729
Copyright © 1999 by the BMJ Publishing Group Ltd.

Tackling antimicrobial resistance

Relevant BNF section: 5.1

Bacteria resistant to antibiotic therapy are becoming much more common and this has led to mounting concern in the UK and worldwide.1–4 Many pathogens are now 'multiresistant', that is, they are resistant to several classes of antimicrobial drug. Infection with such organisms may be particularly difficult to treat. In this article, we briefly discuss how resistance and multiresistance occur. We consider some of the important pathogens involved and the problems they pose in hospitals and the community. We discuss strategies for slowing the accumulation of antibiotic resistance and the implications for doctors treating patients with common infections.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Denamur, S., Van Bambeke, F., Mingeot-Leclercq, M.-P., Tulkens, P. M. (2008). Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. Antimicrob. Agents Chemother. 52: 2236-2238 [Abstract] [Full Text]  
  • (2008). Risks of extended-spectrum beta-lactamases. DTB 46: 21-24 [Abstract] [Full Text]  
  • Clements, H., Stephenson, T., Gabriel, V., Harrison, T., Millar, M., Smyth, A., Tong, W., Linton, C. J (2000). Rationalised prescribing for community acquired pneumonia: a closed loop audit. Arch. Dis. Child. 83: 320-324 [Abstract] [Full Text]